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Zonisamide is a new generation anticonvulsant indicated for the
adjunctivemanagement of partial seizures in adults [1]. The anticonvul-
sant activity of zonisamide is predominantly related to the inhibition of
voltage-gated sodium action potentials and reduction of T-type
calcium-channel currents. Because of its broad mechanism of action,
zonisamide is used for many types of epilepsy and in patients whose
epilepsy is resistant to other antiepileptic drugs (AEDs) [2,3]. There is
insufﬁcient evidence to demonstrate the superior clinical effectiveness
of zonisamide compared to other adjunctive AEDs; however, its long
half-life of 63 h supports convenient once- or twice-daily dosing. In
vitro studies have demonstrated antioxidant and neuroprotective
properties at therapeutic doses, suggesting that zonisamidemay protect
against ischemic damage and recurrent seizure activity [4].
Therapy is generally well tolerated; the most common reported
adverse events include somnolence in 17% of patients and dizziness
and anorexia in 13% of patients. Zonisamide may be an alternativedianastewart18@gmail.com
.M. Bridgeman),
This is an open access article under thin some patients over agents associated with weight gain, such as
valproate or pregabalin [5,6]. Zonisamide is metabolized by acetylation
to N-acetyl zonisamide and reduction to 2-sulfamoylacetyl phenol
(SMAP) by cytochrome P450 isoenzyme 3A4. Zonisamide primarily
undergoes renal excretion with 62% recovered from urine and 3% from
feces following multiple doses [1,7].
The package insert was recently updated to reﬂect a risk of
hyperchloremic, nonanion gap metabolic acidosis due to weak inhibition
of carbonic anhydrase and increased renal excretion of bicarbonate.
Furthermore, according to themanufacturer's label, zonisamide is not rec-
ommended for use in patientswith renal failure (deﬁned by themanufac-
turer as an estimatedGFR b 50mL/min); use of this agent in patientswith
renal insufﬁciency, deﬁned as having a GFR b 60mL/min according to the
National Kidney Foundation's KidneyDisease OutcomesQuality Initiative,
requires slower titration and more frequent clinical monitoring for toxic-
ities and adverse effects. Avoidance of use of zonisamide in individuals
with end-stage kidney disease (e.g., GFR b 15 mL/min or on dialysis) is
prudent based on manufacturer recommendations. Zonisamide has
been associated with a statistically signiﬁcant 8% mean increase in
serum creatinine and blood urea nitrogen in clinical trials; however, this
effect dissipated after therapy was discontinued. Of note, a case report
has demonstrated hypersensitivity syndrome with acute kidney injury
due to zonisamide; however; acute kidney injury has not been previously
reported as an adverse event of zonisamide [7]. We present a case reporte CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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kidney injury in a patient on two separate occasions.
2. Case report
A 33-year-old Caucasian man was admitted to the emergency
department following status epilepticus and loss of consciousness. His
medical history included mental retardation, hypertension, hemiplegia,
and partial-onset epilepsy. The patient had no history of smoking,
alcohol abuse, or known drug allergies. Home medications included
phenytoin 100mg in the morning and 200mg before sleep, zonisamide
200 mg daily, loratadine 10 mg daily, naltrexone 50 mg daily, and pro-
pranolol extended release 120mgdaily. The patient received lorazepam
2mg for seizure management and was intubated for airway protection.
Physical examination on presentation showed normal heart rate and
blood pressure and a slightly elevated temperature of 100.2 °F. Labora-
tory testing included a serum creatinine level of 1.2 mg/dL (reference
range: 0.5–1.2 mg/dL), blood urea nitrogen level (BUN) of 12 mg/dL
(16–23mg/dL), lactate level of 2.9mmol/L (0.5–2.2 mmol/L), total phe-
nytoin level of 6.9 μg/mL (10–20 μg/mL), and albumin level of 4.3 g/dL
(3.5–5 g/dL). Upon consultation with the epileptologist, the patient
was loaded with intravenous phenytoin 1000 mg.
Zonisamide was increased to a regimen of 200 mg–100mg–200 mg
daily, and phenytoin was subsequently maintained at usual doses. On
day 2, he was extubated without complications. Urinalysis revealed
2+protein and 1+blood. Laboratory testing demonstrated an elevated
creatinine phosphokinase (CPK) level of 542 U/L (25–150 U/L), serum
creatinine level of 2.8 mg/dL, and BUN level of 23 mg/dL. Zonisamide
was discontinued on day 3 because of continued evidence of intrinsic
kidney injury including a FENa of 2.6. The total phenytoin concentration
had increased to 23.5 μg/mL, and lacosamide 50mg twice daily was ini-
tiated for adjunctive management. The patient's course was complicat-
ed by fevers and a left lower lobe inﬁltrate treated empirically with
intravenous piperacillin/tazobactam 4.5 g every 8 h. This regimen was
maintained until day 6, at which point serum creatinine level was 1.3
mg/dL, BUN level was 12mg/dL, and both lungs were clear. The patient
was discharged on a three-day regimen of levoﬂoxacin 500 mg,
previous doses of phenytoin, and lacosamide 50 mg twice daily to be
increased to three times daily after one week.
Of note, our patient was restarted on zonisamide as outpatient after
the ﬁrst admission and before the second admission for reasons un-
known to themedical team. The patientwas admitted to the emergency
department ten months later with a similar presentation of status epi-
lepticus, loss of consciousness, and a fever of 102.8 °F. The patient was
managedwith two doses of lorazepam2mg IV and intubated for airway
protection. Regularmedications were unchanged from the previous ad-
mission with the exception of increased zonisamide dosing of 100 mg–
100mg–200mgdaily. Labs of note upon admission included serum cre-
atinine level of 0.9 mg/dL, BUN level of 11 mg/dL, and total phenytoin
level of 10.5 μg/mL. It was suspected that the breakthrough seizures
were due to a compilation of missed doses and an infectious cause.
Broad-spectrum empiric antibiotics were started, including one dose
of ceftriaxone 2 g, vancomycin 1 g every 12 h, and piperacillin/tazobac-
tam 4.5 g every 8 h. Doses of antiepileptic drugs were increased; on day
2, the patient received zonisamide 200 mg three times daily and phe-
nytoin 125 mg twice daily. Labs later that day revealed an elevated
serum creatinine level of 4.7 mg/dL, BUN level of 49 mg/dL, and CPK
level of 4410 U/L. The patient was producing concentrated, tea-
colored urine at approximately 0.13 mL/kg/h. Differential diagnosis of
acute myocardial infarction, Wegener's granulomatosis, and systemic
lupus erythematosus was ruled out through creatinine kinase MB,
DNA, myeloperoxidase, and serine protease 3 antibodies and ANA-
titer studies.
The concern for acute kidney injury due to zonisamidewas such that
it was discontinued, and the patient required one session of hemodialy-
sis on day 3 in conjunction with intravenous ﬂuid hydration.Levetiracetam was initiated at 250 mg twice daily. An ultrasound of
the kidneys demonstrated right-sided perinephritis. Urinalysis results
were similar to the ﬁrst visit, including 1+ protein, 2+ blood, and
1+ ketone bodies. Kidney function was monitored closely, and subse-
quent dialysis sessions were not needed. The patient was extubated to
a nasal cannula on day 3. Subsequent complications included pulmo-
nary inﬁltrates and edema evident on chest X-ray on day 8 for which
the patient received levoﬂoxacin 750 mg every 48 h. Therapy for pneu-
moniawas de-escalated on day 10 to azithromycin 500mgand ceftriax-
one 1 g daily. The patient received empiric piperacillin/tazobactam4.5 g
every 8 h on days 12 through 15 for fever of unknown origin. Pan cul-
tures throughout the hospitalization remained negative. The patient
was discharged on day 18 upon resolution of acute kidney injury; at
discharge, serum creatinine level was 1.1 mg/dL and BUN level was 9
mg/dL. Antiepileptic therapy was changed to phenytoin 100 mg three
times daily and levetiracetam 500 mg twice daily because of concern
that zonisamide had been the cause of acute kidney injury.
3. Discussion
There is only one previously published case report of acute kidney
injury occurringwith zonisamide. A 29-year-old Japaneseman presented
to the hospital with acute kidney injury requiring dialysis secondary to
drug-induced hypersensitivity syndrome two months after initiation of
zonisamide [7]. According to the package insert, impaired renal function
(deﬁned by the manufacturer as a creatinine clearance b 20 mL/min) is
associated with decreased zonisamide clearance. Data from several stud-
ies demonstrate an 8% mean increase in serum creatinine and BUN from
baseline; however, there were no reports of acute kidney injury [1].
Discontinuation of zonisamide is recommended in patients who develop
acute renal failure or experience a signiﬁcant increase in serum creatinine
or BUN [2].
Zonisamide is thought to be the cause of acute renal failure in this
patient because of the temporal relationship demonstrated on two
separate hospital admissions. Baseline kidney function was within nor-
mal range at both admissions anddrasticallyworsened after zonisamide
was increased. Concomitant medications were reviewed by the
intensivists, epileptologist, clinical pharmacist, and nephrologists and
were ruled out for possible drug-induced acute kidney injury. The
results of the urinalysis and FENa indicate intrinsic renal failure. The
detrimental effects from up-titration of zonisamide were likely perpet-
uated by volume depletion and rhabdomyolysis from seizure activity. A
positive myoglobin and the rapid increase in serum creatinine on both
admissions are consistent with muscle injury secondary to seizure
activity, zonisamide, or a combination of the two.
The likelihood of zonisamide causing acute renal failure in this
patient was found to be probable based on the Naranjo Adverse Drug
Reaction Probability Scale [8]. Elevated CPK concentration could have
resulted from rhabdomyolysis secondary to seizure activity; however,
there have been postmarketing reports of rhabdomyolysis in patients
taking zonisamide indicating it may be a sequela of the drug itself [2].
Clinicians should be aware of this potential adverse event and should
closely monitor kidney function in patients being started on, or receiv-
ing increased doses of, zonisamide. Furthermore, this case speaks
to the importance of accurate medication reconciliation procedures in
ensuring safe continuation of therapy. Patients are often poor historians,
but medical records may provide valuable information regarding
pharmacotherapy. In this case, the evidence of acute kidney injury on
the ﬁrst admission should have served to caution against subsequent
use and up-titration.
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